Still Good-Looking Setups

This is an excerpt from Cabot Top Ten Trader, which features the best trades to make every week.  Designed for experienced investors who want even more great growth stock ideas, this advisory recommends the best 10 stocks each month for short-term investment by aggressive growth investors.

The market pulled back today, with biotech stocks causing many growth stocks to sink. At day’s end, the Dow was down 49 points while the Nasdaq lost 41 points.

Not much has changed since last week’s issue—the intermediate-term trend (Cabot Tides) is still up and the broad market remains in decent health (Two-Second Indicator). On the flip side, though, the longer-term trend (Cabot Trend Lines) is still negative and growth stocks remain lackluster, with nearly any stock approaching new high ground meeting with selling pressures.

Overall, the market has handled itself well since the Tides turned positive on October 7; another 2% or 3% drop would put the Tides buy signal at risk, but so far, the action has been normal.  

Individual stocks, on the other hand, have been a different story. Just about any stock that’s approached new high ground has been met with selling, and we’re seeing more breakdowns than breakouts among growth stocks. 

All of that said, there remain lots of good-looking set-ups, so our thought is that the rubber is likely to meet the road during the next three weeks as many resilient stocks report earnings. If most of them react negatively (like we’ve seen with Netflix and Chipotle Mexican Grill during the past few trading days), that would be a sign to continue holding plenty of cash and be very selective on the buy side. However, if we see a bunch of stocks lift off (whether on earnings or not), that would be the signal to lean on the accelerator.

For now, there’s enough evidence to come off the sideline a bit, but we need further confirmation before putting a bunch of money to work.

Michael Cintolo can be found on Google Plus.

Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.


Biogen is the market-share leader in treating multiple sclerosis.


One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >